The REFLEX study: a missed opportunity?

Affiliations

Comment

Gavin Giovannoni. Lancet Neurol. 2012 Jan.

. 2012 Jan;11(1):22-4.

doi: 10.1016/S1474-4422(11)70282-4. Epub 2011 Dec 4.

¹ Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London E1 2AT, UK. g.giovannoni@qmul.ac.uk

No abstract available

Comment on

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comi G, et al. Lancet Neurol. 2012 Jan;11(1):33-41. doi: 10.1016/S1474-4422(11)70262-9. Epub 2011 Dec 4. Lancet Neurol. 2012. PMID: 22146409 Clinical Trial.